Brief: Ironwood Pharmaceuticals Reports Fourth Quarter And Full Year 2021 Results
17/02/2022 12:24
Feb 17 (Reuters) - Ironwood Pharmaceuticals Inc IRWD.O :
* IRONWOOD PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL
YEAR
2021 RESULTS; LINZESS® (LINACLOTIDE) ACHIEVES BLOCKBUSTER STATUS
AS U.S. NET SALES EXCEED $1 BILLION IN 2021
* Q4 NON-GAAP EARNINGS PER SHARE $0.27
* Q4 GAAP EARNINGS PER SHARE $0.25
* QTRLY TOTAL REVENUES $117.1 MILLION VERSUS $116.7 MILLION
* SEES 2022 TOTAL REVENUE $420 MILLION TO $430 MILLION
Source text for Eikon: ID:nBw3RGbJxa
Further company coverage: IRWD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ironwood Pharmaceuticals
See all newsBrief: Ironwood Pharmaceuticals Appoints Tammi Gaskins As Chief Executive Officer
Ironwood Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Ironwood Q2 revenue rises 33%
Brief: Ironwood Pharmaceuticals Repaid In Full $200 Million 1.5% Convertible Senior Notes Due 2026
Brief: FDA Approves Use Of Linzess In Pediatric Patients Aged 2 & Older With Functional Constipation